Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/908 - attachment 3 (PDF)

Found: solution for injection COVID -19 Vaccine (ChAdOx1 S [recombinant]) Therapeutic area: Prevention of coronavirus

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/945 - attachment 2 (PDF)

Found: Gastrointestinal atonic and hypomotility disorders NEC Constipation 4 0 Gastrooesophageal reflux disease

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 6 (PDF)

Found: We used a negative control outcome ,i.e., COVID -19 disease in the first 14 days after time zero to

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 2 (PDF)

Found: 2 (SARS -CoV-2) causes the coronavirus disease 2019 (COVID -19) and has led to a global pandemic.

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 4 (PDF)

Found: severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2) causes coronavirus disease 2019 (COVID

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 1 (PDF)

Found: Regionale di Sanità Della Toscana (Regional Health Agency of Tuscany) AZ AstraZeneca AB COVID -19 coronavirus

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 5 (PDF)

Found: vACcine Covid -19 monitoring readinESS AESI Adverse Events of Special Interest CDC Centers for Disease

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023
Document: FOI 23/905 - attachment 7 (PDF)

Found: Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer- BioNTech Coronavirus

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 27 November 2023
Document: FOI 23/858 - attachment (PDF)

Found: The MHRA state“Validation of any proposed analytical methods must be de monstrated as part of the control

---

Bill Documents
14 Mar 2024 - Keeling schedules
Keeling Schedule showing changes which would be made by the Renters (Reform) Bill (as introduced) and by amendments made at Commons Committee to the Housing Act 1988, should the Bill receive Royal Assent - updated January 2024
Renters (Reform) Bill 2022-23

Found: Notes 1 Coronavirus text removed following the expiry of 2020 c.7 Sch.29 para.6 by Coronavirus Act

---